Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer

The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.

Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news